What are the side effects of intravenous alprostadil?

Intravenous Alprostadil Side Effects

Intravenous alprostadil causes dose-dependent side effects including apnea (requiring immediate respiratory support), fever, flushing, bradycardia, hypotension, and seizures, with apnea being the most critical complication requiring continuous monitoring in neonates with duct-dependent cardiac lesions. 1, 2

Common Side Effects (Dose-Dependent)

The most frequently reported adverse effects of IV alprostadil include:

• Fever occurs commonly and is dose-related 2, 3
• Apnea is the most serious common side effect, occurring in approximately 20% of treated infants and requiring immediate intervention 2, 4
• Flushing results from peripheral vasodilation 2, 3
• Bradycardia develops as a cardiovascular response 2
• Hypotension occurs due to decreased peripheral resistance 1, 4
• Seizures (jitteriness) can occur but are usually easily reversed 2, 4

Cardiovascular Effects

Alprostadil produces systemic hemodynamic changes through its vasodilatory properties:

• Doses of 1-10 micrograms/kg lower blood pressure by decreasing peripheral resistance 1
• Reflex increases in cardiac output and heart rate accompany blood pressure reduction 1
• Peripheral vasodilation is a direct pharmacologic effect 4

Dose-Related Toxicity Pattern

The incidence of side effects is clearly dose-dependent, with lower doses showing improved safety profiles:

• At doses of 0.005-0.01 micrograms/kg/minute, no serious side effects were noted 3
• Higher doses (0.1 micrograms/kg/minute) showed increased side effect incidence 3
• Starting doses typically range from 0.1 micrograms/kg/minute, with maintenance doses as low as 0.002 micrograms/kg/minute 2

Critical Monitoring Requirements

Because alprostadil has a very short half-life (approximately 6 minutes) and up to 80% is metabolized in one pass through the lungs, continuous infusion and monitoring are mandatory:

• Continuous IV infusion is required due to rapid metabolism 1
• Careful monitoring is essential despite side effects occurring in only 20% of patients 4
• Apnea requires immediate respiratory support and is the primary reason for intensive monitoring 2, 4

Metabolic and Excretion Profile

• Primarily metabolized by β- and ω-oxidation in the lungs 1
• Metabolites are excreted by the kidney, with essentially complete excretion within 24 hours 1
• No unchanged alprostadil is found in urine 1
• No evidence of tissue retention of alprostadil or its metabolites 1

Risk-Benefit Consideration

Despite the side effect profile, the benefits of IV alprostadil in duct-dependent cardiac lesions greatly outweigh the risks when proper monitoring is in place:

• Side effects occur in approximately 20% of infants 4
• Most side effects are easily reversed with appropriate intervention 4
• The drug is essential for maintaining adequate pulmonary blood flow or lower body perfusion in neonates with congenital heart defects until surgical correction 2, 4

Clinical Pitfalls to Avoid

• Never assume apnea is related solely to the underlying cardiac condition—it is a direct drug effect requiring dose adjustment or respiratory support 2
• Do not use higher doses than necessary—start with 0.005-0.01 micrograms/kg/minute to minimize side effects 3
• Avoid attributing all symptoms to the cardiac defect—fever, seizures, and hypotension may be drug-induced and reversible 2, 4